Format

Send to

Choose Destination
Epilepsia. 2017 Aug;58(8):e96-e100. doi: 10.1111/epi.13815. Epub 2017 Jun 15.

Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol.

Author information

1
Department of Neuroscience and Physiology, New York University Langone Medical Center, New York, New York, U.S.A.
2
Comprehensive Epilepsy Center, New York University Langone Medical Center, New York, New York, U.S.A.

Abstract

Recent clinical trials indicate that cannabidiol (CBD) may reduce seizure frequency in pediatric patients with certain forms of treatment-resistant epilepsy. Many of these patients experience significant impairments in quality of life (QOL) in physical, mental, and social dimensions of health. In this study, we measured the caregiver-reported Quality of Life in Childhood Epilepsy (QOLCE) in a subset of patients enrolled in a prospective, open-label clinical study of CBD. Results from caregivers of 48 patients indicated an 8.2 ± 9.9-point improvement in overall patient QOLCE (p < 0.001) following 12 weeks of CBD. Subscores with improvement included energy/fatigue, memory, control/helplessness, other cognitive functions, social interactions, behavior, and global QOL. These differences were not correlated to changes in seizure frequency or adverse events. The results suggest that CBD may have beneficial effects on patient QOL, distinct from its seizure-reducing effects; however, further studies in placebo-controlled, double-blind trials are necessary to confirm this finding.

KEYWORDS:

Cannabidiol; Epilepsy; Pediatric; Quality of life; Seizures

PMID:
28617940
PMCID:
PMC5568670
DOI:
10.1111/epi.13815
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center